These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 2005879

  • 21. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
    Reddel RR, Murphy LC, Hall RE, Sutherland RL.
    Cancer Res; 1985 Apr; 45(4):1525-31. PubMed ID: 3978620
    [Abstract] [Full Text] [Related]

  • 22. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.
    Watts CK, Sutherland RL.
    Mol Pharmacol; 1987 May; 31(5):541-51. PubMed ID: 3553893
    [Abstract] [Full Text] [Related]

  • 23. Species-specific pharmacology of antiestrogens: role of metabolism.
    Jordan VC, Robinson SP.
    Fed Proc; 1987 Apr; 46(5):1870-4. PubMed ID: 3556610
    [Abstract] [Full Text] [Related]

  • 24. Pharmacological activities of droloxifene isomers.
    Löser R, Seibel K, Huber HJ.
    Anticancer Res; 1988 Apr; 8(6):1271-4. PubMed ID: 3218958
    [Abstract] [Full Text] [Related]

  • 25. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC, O'Regan RM, Gajdos C, Robinson SP, Bentrem D, De Los Reyes A, Jordan VC.
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [Abstract] [Full Text] [Related]

  • 26. Antiestrogen pharmacology and mechanism of action.
    Katzenellenbogen BS, Miller MA, Eckert RL, Sudo K.
    J Steroid Biochem; 1983 Jul; 19(1A):59-68. PubMed ID: 6887873
    [Abstract] [Full Text] [Related]

  • 27. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER.
    Jiang SY, Langan-Fahey SM, Stella AL, McCague R, Jordan VC.
    Mol Endocrinol; 1992 Dec; 6(12):2167-74. PubMed ID: 1491696
    [Abstract] [Full Text] [Related]

  • 28. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro.
    Reddel RR, Sutherland RL.
    Cancer Res; 1987 Oct 15; 47(20):5323-9. PubMed ID: 3652038
    [Abstract] [Full Text] [Related]

  • 29. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    MacGregor Schafer J, Liu H, Bentrem DJ, Zapf JW, Jordan VC.
    Cancer Res; 2000 Sep 15; 60(18):5097-105. PubMed ID: 11016635
    [Abstract] [Full Text] [Related]

  • 30. Non-steroid receptor-mediated antiproliferative activity of styrylpyrone derivative in human breast cancer cell lines.
    Pihie AH, Stanslas J, Din LB.
    Anticancer Res; 1998 Sep 15; 18(3A):1739-43. PubMed ID: 9673398
    [Abstract] [Full Text] [Related]

  • 31. Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro.
    Reddel RR, Murphy LC, Sutherland RL.
    Cancer Res; 1983 Oct 15; 43(10):4618-24. PubMed ID: 6883318
    [Abstract] [Full Text] [Related]

  • 32. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer.
    Toko T, Shibata J, Nukatsuka M, Yamada Y.
    Cancer Chemother Pharmacol; 1997 Oct 15; 39(5):390-8. PubMed ID: 9054952
    [Abstract] [Full Text] [Related]

  • 33. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D, Dardes R, Liu H, MacGregor-Schafer J, Zapf J, Jordan V.
    Endocrinology; 2001 Feb 15; 142(2):838-46. PubMed ID: 11159857
    [Abstract] [Full Text] [Related]

  • 34. Antitumor mechanism of action of a cyclopropyl antiestrogen (compound 7b) on human breast cancer cells in culture.
    Jain PT, Pento JT, Magarian RA.
    Cancer Chemother Pharmacol; 1996 Feb 15; 38(3):238-44. PubMed ID: 8646798
    [Abstract] [Full Text] [Related]

  • 35. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
    Pavlik EJ, Nelson K, Srinivasan S, Powell DE, Kenady DE, DePriest PD, Gallion HH, van Nagell JR.
    Cancer Res; 1992 Aug 01; 52(15):4106-12. PubMed ID: 1638522
    [Abstract] [Full Text] [Related]

  • 36. Acetaminophen-induced proliferation of breast cancer cells involves estrogen receptors.
    Harnagea-Theophilus E, Gadd SL, Knight-Trent AH, DeGeorge GL, Miller MR.
    Toxicol Appl Pharmacol; 1999 Mar 15; 155(3):273-9. PubMed ID: 10079213
    [Abstract] [Full Text] [Related]

  • 37. Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13.
    Strobl JS, Peterson VA.
    J Pharmacol Exp Ther; 1992 Oct 15; 263(1):186-93. PubMed ID: 1403784
    [Abstract] [Full Text] [Related]

  • 38. Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7.
    Roos W, Oeze L, Löser R, Eppenberger U.
    J Natl Cancer Inst; 1983 Jul 15; 71(1):55-9. PubMed ID: 6575210
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.
    Jordan VC, Gosden B.
    Endocrinology; 1983 Aug 15; 113(2):463-8. PubMed ID: 6872937
    [Abstract] [Full Text] [Related]

  • 40. Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro.
    Jordan VC, Koch R, Langan S, McCague R.
    Endocrinology; 1988 Apr 15; 122(4):1449-54. PubMed ID: 3345720
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.